| (Values in U.S. Thousands) | Jun, 2024 | Jun, 2023 | Jun, 2022 | Jun, 2021 | Jun, 2020 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -1,820 | -2,660 | -2,660 | -2,030 | -4,740 |
| Net Income Growth | +31.58% | unch | -31.03% | +57.17% | +17.71% |
Propanc Biopharma Inc (PPCBD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Propanc Biopharma, Inc. is a healthcare company. It focuses on the development of cancer treatments for pancreatic, ovarian and colorectal cancer primarily in Australia. The Company's products include PRP and PRP-DCM. Propanc Biopharma, Inc., formerly known as Propanc Health Group Corporation, is based in Camberwell, Australia.